Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)
A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination with Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients with Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and with Presence of Injectable Metastases
Sponsor: Merck Sharp & Dohme LLC
A PHASE2 clinical study on Melanoma Stage III and Melanoma Stage IV, this trial is actively recruiting participants. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Nov 2024 — Present [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — May 2024 [monthly]
Active Not Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Philogen S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .